Subscribe
e.g. organoids

Icahn School of Medicine at Mount Sinai Secures $5 Million NIH Grant for Cutting-Edge Cancer Target Discovery and Development Center

The Department of Immunology and Immunotherapy and the Icahn Genomics Institute at the Icahn School of Medicine at Mount Sinai have been awarded a $5 million grant from the National Cancer Institute (NCI) to establish a state-of-the-art center dedicated to the discovery and development of cutting-edge targets for cancer therapy.
[Icahn School of Medicine (EurekaAlert)]
Press Release
Published In
NewslettersImmune Regulation News
spot_img

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News

FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T Cell Immunotherapies

[FDA] The FDA has received reports of T cell malignancies, including chimeric antigen receptor CAR-positive lymphoma, in patients who received treatment with BCMA- or CD19-directed autologous CAR T cell immunotherapies.
Cell Therapy NewsNewsletters
Read more

Modular Chimeric Cytokine Receptors with Leucine Zippers Enhance the Antitumour Activity of CAR T Cells via JAK/STAT Signaling

[Nature Biomedical Engineering] Investigators showed that replacement of the extracellular domains of heterodimeric cytokine receptors in T cells with two leucine zipper motifs provided optimal Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling.
Cell Therapy NewsNewsletters
Read more

CAR+ T Cell Lymphoma Post Ciltacabtagene Autoleucel Therapy for Relapsed Refractory Multiple Myeloma

[blood] The authors presented the clinicogenomic characterization of a CARTITUDE-4 patient who developed a CAR+ T cell lymphoma post cilta-cel. Diagnostic and staging workup included biopsy analyses and FDG-PET scan.
Cell Therapy NewsNewsletters
Read more
Brought to you by